Lipum has signed the grant agreement for BEYOND, a project selected by Horizon Europe under the call “Boosting the translation of biotech research into innovative health therapies”. The project has been awarded a total grant of approximately EUR 8 million, [...]

Lipum today announced that results from the First-in-Human (FIH) Phase I trial of its drug candidate SOL-116 have been published in the peer-reviewed journal RMD Open. SOL-116 is a first-in-class humanised monoclonal antibody targeting bile salt-stimulated lipase (BSSL), a novel [...]